Marksans Pharma is currently trading at Rs. 32.45, up by 0.65 points or 2.04% from its previous closing of Rs. 31.80 on the BSE.
The scrip opened at Rs. 33.35 and has touched a high and low of Rs. 33.35 and Rs. 30.25 respectively. So far 2357417 shares were traded on the counter.
The BSE group ‘B’ stock of face value Rs. 1 has touched a 52 week high of Rs. 33.35 on 08-Jun-2020 and a 52 week low of Rs. 9.90 on 24-Mar-2020.
Last one week high and low of the scrip stood at Rs. 33.35 and Rs. 23.00 respectively. The current market cap of the company is Rs. 1344.60 crore.
The promoters holding in the company stood at 48.25%, while Institutions and Non-Institutions held 3.43% and 48.32% respectively.
Marksans Pharma has issued voluntary recall of one batch of Metformin Extended Release Tablets USP 500 mg (11279 bottles, Lot No. XP9004) due to detection of NDMA as a matter of abundant precaution.
Metformin Extended Release Tablets USP 500 mg is indicated as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes mellitus.
Marksans Pharma together with its subsidiaries operates as an integrated international pharmaceutical company. The company’s business is distribution of pharmaceutical products.
